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Abstract
Objectives To compare the effects of typical and atypical
antipsychotic drugs on sleep activity and subjective sleep
quality.
Design Randomised, double-blind, placebo-controlled,
four-period cross-over, clinical trial was used to evaluate
the effects of active treatments on objective and subjective
sleep variables.
Setting Sleep laboratory evaluation.
Participants Twenty healthy young volunteers, both sexes.
Interventions Single oral morning administrations of olan-
zapine 5 mg, risperidone 1 mg, haloperidol 3 mg and
placebo.
Measurements and results Five polysomnographic nights
were evaluated: one control night and one after each
intervention. Significant increase in total sleep time, sleep
efficiency, slow wave sleep (SWS) and rapid eye move-
ment (REM) sleep with decreases in wake time were
observed after olanzapine. Decreases in wake time, REM
sleep and stage shifts together with increases in stage 2
were obtained after risperidone. Haloperidol showed only a
tendency to increase sleep efficiency and stage 2 and to
decrease wake time. Olanzapine showed decreases in
power density in frequencies higher than 10 Hz during
all sleep stages and in frequencies lower than 5 Hz range
in SWS; decreases in the dynamics of spindle frequency
activity (SFA) in the second and fourth non-rapid eye
movement (NREM) episodes were also obtained. Risper-
idone presented increases in the 3.6–10.8 Hz frequency
range in NREM sleep stages and in stage 2. Haloperidol
also showed increases in NREM sleep stages and in stage
2, but these were in frequencies higher than 10 Hz, with
increases in the dynamics of SFA in the first NREM
episode. Only a significant improvement in subjective
sleep quality was observed after olanzapine.
Conclusions Antipsychotics showed different sleep
changes as their neurochemical profiles were distinct. These
changes were observed even when the drug was adminis-
tered 15 h before going to bed.
Keywords Antipsychotics . Polysomnography .
Spectral analysis . Subjective evaluations .
Healthy volunteers . Single morning oral intake
Introduction
Antipsychotic agents have been widely used since their
introduction in the 1950s primarily in the treatment of
schizophrenia and other psychotic disorders (Tandon
1998). Phenothiazines, butyrophenones and thioxanthines
constitute the group of classical or typical antipsychotic
drugs. Chlorpromazine and haloperidol are commonly
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taken as prototypes for this group. Their main pharmaco-
logic activity is to block dopamine D2 receptors, and their
principal benefits include control of active psychotic
symptoms, management of severe agitation and reduction
in assaultive behaviour and risk of psychotic relapse
during maintenance treatment. However, they have inher-
ent limitations, especially in treating negative and cogni-
tive deficits associated with schizophrenia (Worrel et al.
2000). Their side effects include anticholinergic effects,
hyperprolactinemia, short-term movement disorders (ex-
trapyramidal side effects) and potential long-term move-
ment disorders (tardive dyskinesia) (Tandon 1998).
Atypical antipsychotic drugs were developed in response
to these drawbacks. They include dibenzodiazepines
(clozapine and quetiapine), benzisoxazoles (risperidone),
and thienobenzodiazepines (olanzapine). In addition to the
blockage of dopamine D2 receptors, they also act as
antagonists on serotonin 5-hydroxytryptamine (5-HT)2
receptors. Atypical antipsychotics improve efficacy in
refractory patients, have broader efficacy in treating
positive and negative symptoms, improve cognitive
functioning, lower the incidence of movement disorders
and show minimal perturbation on serum prolactine levels
(Worrel et al. 2000).
Assessing drug-induced effects on sleep in healthy
young volunteers is a valuable contribution towards
understanding drug–disease interactions because conclu-
sions concerning the pharmacological effects of a com-
pound per se on sleep may be drawn in the absence of
confusing factors such as the pathological condition,
lifestyle or adverse events (Warrington 1997). Despite its
widespread use in visual sleep scoring, the conventional
Rechstschaffen and Kales (R&K) criteria provide insuffi-
cient information about the continuity of sleep stages. It has
been shown that all-night spectral analysis is a sensitive
method for documenting pharmacological effects on sleep
EEG (Borbély et al. 1983). It not only detects shifts
between the various sleep stages during the night, but also
takes into account the qualitative alterations of certain
stages (Schlösser et al. 1998).
Thus, the aim of the current study was to evaluate the
sleep effects of two atypical antipsychotic drugs (olanza-
pine and risperidone), showing different brain neurobio-
chemical interactions, in comparison with those of a typical
agent (haloperidol). We used a design, which would
highlight two important points: (1) cross-over in young
healthy subjects (to control for interindividual differences
and disease bias) and (2) a single morning administration
(to assess night effects and highlight the non-compartmental
nature of the wake–sleep cycle). We emphasised all-night
sleep EEG spectral analysis, although the traditional R&K
procedure was also applied for comparison purposes with
previous studies.
Materials and methods
Study population
Healthy young adult volunteers of either gender were
selected from the pool of volunteers at the Pharmacology
Research Unit (Research Institute), Santa Creu i Sant Pau
Hospital, Barcelona, Spain. Medical interviews and exami-
nations, clinical chemistry, haematology and urinalysis tests
were performed within 21 days before study initiation.
Exclusion criteria included any history of medical or
psychiatric illness (non-patient version of the Structured
Clinical Interview for DSM-IV), and all participants were
screened for subjective sleep disturbances (Pittsburg Sleep
Quality index<5). The first polysomnography (PSG) night,
in addition to familiarisation purposes, allowed us to
objectively exclude any undiagnosed sleep disorder (AHÍ<
5/h; PLMI<5/h). Pre-study examinations also included drug
screening, serological testing (for hepatitis B and C and
HIV) and serum pregnancy test for women. The subjects’
habitual alcohol, coffee and cigarette consumptions were
insufficient to provoke withdrawal effects when the sub-
stances were not allowed in the 24 h before and after each
study day, as it was required in this study (≤39 g absolute
alcohol/day, ≤100 mg caffeine/day, ≤5 cigarettes/day). No
strenuous physical exercise or naps were allowed in the 24 h
before each experimental session or in the following 24 h.
Participants were requested not to take any medication
during the study without the investigator’s prior knowledge
and were asked to keep regular sleep–wake habits in the
month before the study and during the study itself. The latter
was verified by checking individual sleep diaries.
The trial was approved by the center’s Research Ethics
Committee and the Spanish Drug Agency, and was
conducted following the principles stated in the Declaration
of Helsinki and Good Clinical Practice guidelines. All
volunteers gave written informed consent before the start of
the trial and were paid for their participation.
Study design
A randomised, double-blind, placebo-controlled, four-period
cross-over design was used to evaluate the effects of active
treatments on objective and subjective sleep variables. Drugs
were orally administered in the morning (8 A.M.) under
fasting conditions at the following dosages: olanzapine
5 mg, risperidone 1 mg, and haloperidol 3 mg. These
dosages, although lower than clinical doses at the low
effective therapeutic range (olanzapine 10 mg/day, risper-
idone 2 mg/day and haloperidol 5 mg/day; Miyamoto et al.
2002) as they were administered to healthy volunteers can
roughly be considered as equipotent for a pharmacodynam-
ic point of view. After drug intake, the subjects remained
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the whole day in the laboratory where spontaneous
vigilance-controlled EEG recordings were assessed at
different time points. They were under continuous supervi-
sion and were not allowed to nap. Results from the
pharmaco-EEG mapping study have been separately pub-
lished in summary form (Barbanoj et al. 2004). A 1-week
washout window before the administration of the next
treatment was established. Subjects spent a total of ten
nights in the sleep laboratory. The first night was
considered an adaptation night to familiarise volunteers
with the laboratory and recording procedures whereas the
second was considered a control night, and no medication
was given. All volunteers performed these two nights
within 3 weeks before the study period. Each experimental
period included a baseline night, morning drug administra-
tion, full-day under controlled vigilance conditions and
following night in the sleep laboratory. Results from the
control night and from the four nights after drug adminis-
tration were considered for the final sleep evaluations.
Sleep recordings were performed in individual, sound-
attenuated, temperature-regulated rooms, and volunteers were
supervised by qualified technical staff. Volunteers started
sleep procedures by 8.00 P.M. and had dinner by this time.
The total time in bed was fixed at 8 h. The lights were
turned off around 11.00 P.M. and turned on around 7 A.M. the
following morning. In addition, no later than 15 min after
having woken up each morning, the volunteers completed a
self-rating scale on their subjective quality of sleep and
awakening (SSA; Saletu et al. 1987a).
Recordings and sleep stage classification
Two computed PSG systems were used: Coherence 32E-
Deltamed and Sleep Lab-Aequitron Medical Recordings. The
same system was used for all recordings from each volunteer.
The recordings consisted of six EEG channels (Fp1, Fp2, C3,
C4, O1, O2 referenced to average mastoid [A1–A2], accord-
ing to the international 10–20 system), 2 electrooculographic
leads (EOG; right and left, recorded between the two external
canthi, with capacity to detect ocular movements in both
directions: horizontal and vertical), and 1 chin electromyo-
graphic channel (EMG), consisting of two electrodes placed
on the submentonian muscles, which monitored muscular
tone. Four channels were included to monitor the respiratory
function, one for airflow signal, two channels to record rib
cage and abdominal motion, and a fourth for oxygen
saturation. Heart rate variability was controlled by means of
an electrocardiogram (ECG) channel. Finally, limb move-
ments were monitored using two channels with linked
electrodes on both right and left anterior tibialis. EEG and
EOG channels were filtered to a bandwidth of 0.1–75 Hz with
a sensitivity of a 10μV/mm. EMGwas filtered to a bandwidth
of 10–75 Hz with a sensitivity of 50 μV/mm. A 50-Hz notch
filter was used to attenuate electrical noise. The electrodes
were gold-plated. Channels were calibrated before each
recording, and the electrode impedance was kept below
10 KΩ.
The sleep recordings were visually scored in a 30-s
epoch resolution according to the traditional standard R&K
criteria (Rechtschaffen and Kales 1968) using the View and
Rate (Cdatentechnik GbR, © 1995–1999 3.02 version)
program. Analysis was performed by two independent sleep
scorers. Discrepancies were solved by a third expert from
the same laboratory. Each scorer was blinded to the other
raters’ analysis and medication status.
Sleep variables were derived by visual scoring using
standard criteria, and were classified into three groups: (1)
sleep initiation and maintenance, (2) sleep architecture and
(3) number and average duration of non-rapid eye movement
(NREM) and rapid eye movement (REM) periods and sleep
cycles. Completed NREM–REM cycles were defined from
the onset of stage 2 sleep until the end of REM sleep.
EEG power spectra
EEG signal was high-pass (0.3 Hz) and low-pass (35 Hz)
filtered before being converted from analogue to digital, with
a sampling frequency of 256 Hz. Power spectra of 5-s artefact-
free epochs, weighted by a Hanning window, were computed
using the Fast Fourier Transform and matched with the sleep
scores. Artefact epochs containing either saturation or muscle
activity were automatically identified and eliminated. Power
density values (C4A1 derivation) were averaged into 0.4 Hz
(0.2–6.0 Hz) and 0.8 Hz (6.2–26.0 Hz) bins. The spectra were
calculated separately for non-rapid eye movement sleep
(NREMS; stages 1, 2, 3 and 4), stage 2 (S2), slow wave
activity (slow wave sleep [SWS], stages 3 and 4) and REMS.
Dynamics of slow wave activity (SWA), spindle frequency
activity (SFA) during whole night and delta EOG activity
during REM sleep (DEA)
Power spectra in delta (0.5–4.0 Hz) and sigma (11.0–
15.0 Hz) activities in C4A1 derivation during the whole
night and in delta (0.5–4.0 Hz) in EOG channels during
REM sleep was obtained from 5-s artifact-free epochs.
Slow activity in EOG channels during REM sleep was used
as representative of phasic REM activity intensity. A
moving average estimation of 5 min duration was computed
to smooth their time course through the night. Consecutive
NREM–REM cycles were defined according to modified
criteria of Feinberg and Floyd (1979). NREM episodes
starting with stage 2 and containing at least 15 min of
stages 2, 3 and 4 were succeeded by REM episodes of at
least 5 min duration. For the completion of the first cycle,
no minimal criterion for the REM duration was applied.
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To compensate for the individual differences in the
occurrence and duration of the NREM–REM cycles, a
method derived from Aeschbach and Borbély (1993) was
used. For SWA and SFA, each NREM period of unequal
length was subdivided into 24 equal parts, and each REM
period into four equal parts. They were then averaged
across subjects. For DEA, each REM period of unequal
length was subdivided into 24 equal parts and averaged
across subjects. Changes in the three dynamic activities
were evaluated on the raw data by calculating areas under
the curves (AUC) in each cycle.
Sleep and awakening quality self-rating scale.
A Spanish (Castellano) translation of the questionnaire
“self-assessment scale for sleep and awakening quality
(SSA)” was used (Saletu et al. 1987a). All subjects were
fluent in Spanish (Castellano) even in cases where this
was not the mother tongue. The SSA consists of 20 items
comprising three categories: (1) SSA-1 (seven items),
which evaluates subjective sleep quality, (2) SSA-2 (eight
items), evaluating subjective awakening quality, (3) SSA-
3 (five items), evaluating the presence of somatic
complaints. Responses are coded according to an ordinal
scale with 4 possibilities (not at all, slightly, moderately,
extremely). In the coding process, the values 1, 2, 3 or 4
are assigned in such a way that a higher score means a
worse subjective quality, with the theoretical score ranging
from 20 to 80 for the global scale (SSA), 7 to 28 for SSA-
1, 8 to 32 for SSA-2 and 5 to 20 for SSA-3. Furthermore,
the questionnaire presents five additional open questions
related to different moments of the night, from which
subjective sleep latency (SSL) and subjective sleep
efficiency (SSE) are calculated.
Statistical analysis
The similarity between PSG and SSA target variables on
the control night and the night participants took placebo
was evaluated by means of t tests for repeated measures.
To assess the effects of the various active treatments on
PSG and SSA, general lineal models (GLM) with one within-
subject factor (treatment, 4 levels) were applied to each
variable separately. In all variables, results were pair-
compared by means of t test for repeated measures if
required. Greenhouse-Geisser ɛ correction was used. To
assess the effects on EEG power spectra at the different sleep
stages and on the AUCs of its dynamics, t tests for repeated
measures were applied to each frequency bin or AUC,
respectively, comparing placebo with any active treatments.
Differences were considered significant when the prob-
ability of a type I error was less than 0.05. SPSSWIN
version 6.1 was utilized.
Results
Study population
The study sample was made up of 20 healthy young
volunteers (ten men and ten women). Mean age was
26.9 years (range 21–37), mean weight was 64.3 kg (range
51.0–86.5) and mean height was 167.5 cm (range 158–
186). Due to technical problems related to computer
software, the data of three subjects had to be excluded
from the analysis, leaving a final total of 17 (nine men and
eight women). No significant differences were observed
between the total and the evaluated sample in these
demographic characteristics. All participants completed
the trial and were compliant with the study protocol, and
all active treatments were well tolerated.
PSG sleep variables
No significant differences were observed in any sleep
initiation and maintenance, sleep architecture, nor NREM–
REM period variables evaluated between the control night
and the night with placebo.
Sleep initiation and maintenance
Sleep latencies were shorter after all treatments but did
not reach statistical significance in any case. A statistically
significant decrease was obtained in REM latency after
olanzapine in relation to risperidone. Latency in SWS
sleep presented the opposite pattern, with olanzapine
showing the longest latency and risperidone the shortest
(Table 1).
Significant differences between treatments were ob-
served in total sleep time (TST), sleep efficiency and wake
time, both when computed as a percentage of TST and
when calculated in absolute minutes. Olanzapine signifi-
cantly increased TST and sleep efficiency in comparison
with all the other treatments. It significantly decreased wake
time in comparison with placebo and haloperidol. A
statistically significant decrease in wake time when evalu-
ated in total number of minutes was observed after
risperidone in comparison to placebo (Table 1).
Sleep architecture
No significant effects were observed in sleep stage 1 or
movement time. However, olanzapine showed significantly
less sleep stage 1 in relation to placebo. On the other hand,
significant differences between treatments were observed in
sleep stages 2, SWS and REM. Significant increases were
obtained in stage 2 after risperidone compared to placebo,
olanzapine and to a lesser extent to haloperidol. Significant
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increases in SWS were observed after olanzapine in relation
to all the other treatments. Significant increases in REM
sleep were obtained after olanzapine in relation to placebo.
However, significant decreases in REM sleep were ob-
served after risperidone in relation to olanzapine and
haloperidol (Table 2).
Stage shifts during time in bed presented significant
differences between treatments. Risperidone showed sig-
nificantly fewer shifts than placebo and haloperidol, and
olanzapine showed significantly fewer shifts than haloper-
idol (Table 2).
NREM–REM periods
Although no significant differences between treatments
were observed in any NREM–REM period variables,
significant increases after olanzapine in average duration
of sleep cycles in relation to placebo, in average NREM
periods in relation to placebo and haloperidol and in average
REM periods in relation to risperidone, were obtained.
Spectral analysis
EEG power spectra
Mean all-night power spectra is presented in Fig. 1. The
values for drug nights are expressed as a percentage of the
placebo night.
NREMS power spectrum showed a different pattern
depending on the active treatment. Statistically significant
values below the placebo level were obtained after
olanzapine in the high-frequency range (frequencies higher
than 10 Hz). After risperidone and haloperidol, statistically
significant values above the placebo level were reached.
These were within the 3.6–10.8 Hz frequency band after
risperidone and at frequencies above 18 Hz after haloper-
idol. The spectrum in stage 2 was very similar to that of
NREMS except for an additional significant increase of
power at the 0.8–1.2 bins after risperidone. However, the
SWS spectrum showed different results. Olanzapine in-
duced additional significant reductions, at the 0.8–4.8
frequency band, and risperidone induced significant
increases within the high-frequency range bins (14.8–16.4,
18.8, 22.0, 24.4). No significant changes were observed
after haloperidol. In REMS, power density was significant-
ly reduced in comparison to placebo after olanzapine in the
11.6–22.0 Hz frequency range and was increased after
haloperidol at the 5.2–5.6 bins.
Dynamic of SWA
On all nights, either after placebo or active drugs, SWAwas
higher in NREMS and lower in REMS, and a declining
trend was presented over consecutive NREMS episodes.
No significant changes were observed in the amount of
SWA between any active treatment and placebo. Dynamics
Table 1 Sleep initiation and maintenance measures after one single oral morning administration of olanzapine 5 mg, risperidone 1 mg and
haloperidol 3 mg (means±SEM; n=17)
Control Placebo Olanzapine Risperidone Haloperidol Manova Paired t test
Latency to
stage 1 (min)
13.23±13.2 13.5±27.36 5.3±6.1 14.6±23.4 9.6±11.8 0.527
Latency to
stage 2 (min)
22.7±18.23 16.4±28.7 9.9±8.1 17.9±23.3 12.6±11.3 0.346
Latency to
delta (min)
16.1±5.06 18.7±19.98 21.2±15.4 16.2±8.9 17.97±7.9 0.739
REM Latency (min) 84.3±37.43 83.8±31.2 66.6±27.8 85.9±28.9 82.2±32.05 0.119 R vs O**; R vs P+
Time in bed (min) 480.4±2.33 479.1±4.23 477.9±7.9 479.1±2.03 476.9±9.4 0.781
Total sleep
period (min)
456.5±17.6 462.1±29.03 467.9±10.5 450.9±37.2 460.3±20.1 0.169
Total sleep
time (min)
436.5±36.48 422.5±59.6 461.6±13.3 438.1±43.3 444.2±28.3 0.013 O vs P**; O vs H**; O vs R*
Sleep efficiency (%) 90.9±7.66 88.2±12.37 96.6±2.63 91.4±9.06 93.2±5.9 0.005 O vs P**; O vs H**; O vs R*;
P vs H+
Wake/TSP (min) 19.9±50.1 39.5±49.3 6.2±8.2 12.8±15.3 16.1±19.02 0.010 O vs P**; O vs H*; O vs R+;
P vs R*; P vs H+
Wake/TSP (%) 4.3±12.1 8.62±11.1 1.34±1.75 2.9±3.4 3.5±4.15 0.011 O vs P*; O vs H*; O vs R+;
P vs H+; P vs R+
P placebo, O colanzapine, R risperidone, H haloperidol
+p<0.10
*p<0.05
**p<0.01
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of SWA throughout the night after all experimental
interventions are presented in Fig. 2.
Dynamic SFA
The typical pattern of SFA with low values in REMS
episodes, and higher level, U-shaped pattern (with lowest
values coinciding with highest values of SWA) in NREMS,
was presented either after placebo or active drugs. Differ-
ences were observed after treatments. In comparison with
placebo, SFA was significantly decreased after olanzapine
in the second (t=2.86, df=16, p<0.010) and fourth (t=2.66,
df=5, p=0.045) NREM sleep episodes and enhanced in the
first NREM episode after haloperidol (t=3.01, df=16, p<
0.01; Fig. 2).
Dynamic of slow activity in EOG channels (DEA)
during REM sleep
Slow activity in EOG channels during REM sleep did not
present any significant changes on any night either after
placebo or active drugs.
Subjective sleep and awaking quality
No significant differences were observed in any subjective
sleep or awakening quality variables evaluated between the
control night and the night with placebo (Table 3).
No significant treatment effects were observed in the
total score, in the awaking quality score or in the somatic
complaints. There was a significant improvement in
subjective sleep quality after olanzapine in comparison to
risperidone and haloperidol and a tendency towards
improvement in comparison to placebo. Although SSL
and SSE did not show significant treatment effects,
olanzapine and haloperidol showed a decrease in the former
and an increase in the latter in comparison to placebo.
Discussion
This double-blind, placebo-controlled, four-period, cross-
over sleep laboratory investigation in healthy volunteers
involved the morning intake of olanzapine 5 mg, risper-
idone 1 mg and haloperidol 3 mg. Significant distinct
changes on sleep were observed after going to bed 15 h
after drug administration. Although the neuroleptic’s effects
of sleep seem well documented, to date, there are only two
controlled studies in healthy subjects after olanzapine
(Sharpley et al. 2000; Lindberg et al. 2002), one controlled
study after risperidone (Sharpley et al. 2003), and none
after haloperidol. The effects of these drugs on sleep have
not been evaluated previously after morning administration,
and only in one study after olanzapine have the data been
analysed using EEG spectral power (Lindberg et al. 2002).
As the study was a crossover design balanced for sequence,
Table 2 Sleep architecture measures after one single oral morning administration of olanzapine 5 mg, risperidone1mg and haloperidol 3 mg
(mean±SEM; n=17)
Control Placebo Olanzapine Risperidone Haloperidol Manova Paired t test
Stage 1 (min) 15.6±10.15 18.4±10.5 13.7±7.8 17.0±22.7 18.4±9.87 0.332 O vs P*
Stage 1 (%) 3.6±2.3 4.5±2.69 2.9±1.75 2.82±2.63 4.18±2.23 0.075
Stage 2 (min) 246.9±44.26 220.15±43.10 227.7±45.25 258±39.1 239.8±30.8 0.018 R vs P**; R vs O*;
H vs P+
Stage 2 (%) 56.7±5.26 52.2±7.64 49.4±10.17 58.9±6.9 53.9±5.7 0.001 R vs P** ; R vs O**;
R vs H*; H vs O+
SWS (min) 74.9±27.02 89.3±28.5 113.2±43.7 82.7±30.3 80.5±24.1 0.001 O vs H**; O vs R**;
O vs P*
SWS (%) 17.8±4.07 23.7±14.4 24.5±9.21 18.8±6.3 18.5±5.4 0.032 O vs H**; O vs R*
REM (min) 91.2±34.9 90.8±33.37 103.7±19.0 82.3±22.9 101.3±23.1 0.008 R vs O**; R vs H*;
O vs P+
REM (%) 20.6±5.15 21.1±6.27 22.43±3.9 18.7±4.8 22.7±4.9 0.021 R vs O*; R vs H*;
R vs P+; O vs P*
Stage shifts /TIB 74.3±20.8 69.9±18.3 56.2±21.16 53.4±18.9 69.6±18.9 0.008 R vs P**; R vs H**;
O vs H**
Movement time (min)/
TSP
4.6±3.75 3.9±3.3 3.1±3.65 2.9±2.52 1.05±1.05 0.488
Movement time (%)/TSP 1.1±0.8 0.8±0.71 0.7±0.7 0.65±0.53 1.05±1.05 0.566
P placebo, O olanzapine, R risperidone, H haloperidol
+p<0.10
*p<0.05
**p<0.01
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the lack of significant differences in any PSG variables and
subjective reports between the control night and the night
with placebo indicate an adequate adaptation to the sleep
laboratory conditions and guarantee the relevance of the
analysis strategy selected, that is, the application of GLM
directly to the row data after each experimental intervention
without any adjustment for baseline recordings.
Regarding PSG effects, olanzapine showed a consistent
hypnotic effect by increasing TST and sleep efficiency and
decreasing wake time. The reduced sleep latency onset,
although not statistically significant, agreed with this
pattern. Concerning sleep architecture, SWS and REM
sleep were increased. Significant increases in the average
duration of sleep cycles and in both NREM and REM
periods, mainly in the former, were also obtained. Results
on sleep initiation and maintenance measures, as well as on
SWS, are in concordance with previous reports where
olanzapine was found to improve sleep continuity and
produce dose-related SWS increases in schizophrenic
(Salin-Pascual et al. 2004) and healthy volunteers (Sharpley
et al. 2000; Lindberg et al. 2002). Olanzapine is a potent 5-
HT2A/2C antagonist, and studies in humans and animals
have shown that 5-HT2A/2C receptors, primarily 5-HT2C, are
involved in the regulation of SWS (Sharpley et al. 1994).
Accordingly, it has been calculated that the 50% increase in
SWS observed after olanzapine (5 mg) corresponds to a
central occupancy of 5-HT2C receptors of at least 70%. On
the other hand, the blockade of histamine-H1 receptors and
alpha1 adrenoreceptors has also been proposed as a possible
mechanism underlying some of the hypnotic effects of
olanzapine such as the decrease in sleep latency onset
(Sharpley et al. 2000) and wake time (Sharpley et al. 2000;
Lindberg et al. 2002; Salin-Pascual et al. 2004). Regarding
the results on REM variables, in the present study we
observed an increase in REM sleep and a non-significant
reduction in REM latency, in clear contrast with the
decrease in REM percentage commonly reported after
olanzapine intake (Sharpley et al. 2000; Lindberg et al.
Fig. 1 EEG power density (C4A1-derivation) in NREM sleep
(NREMS, stages 1, 2, 3 and 4), stage 2 (S2), slow wave sleep
(SWS, stages 3 and 4) and REM sleep (REMS) after one single oral
morning administration of olanzapine 5 mg, risperidone 1 mg and
haloperidol 3 mg. For each frequency bin (n=17), means were
expressed as a percentage of the corresponding value after placebo
(horizontal dashed lines at 0%). Asterisks at the bottom of the panels
indicate frequency bins which differed significantly from placebo (p<
0.05, t tests for repeated measures)
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2002). However, data on REM are far from consistent. In
these earlier studies significances were obtained only at
doses of 10 mg(not at 5 mg) (Sharpley et al. 2000) and only
in the subgroup of female participants (Lindberg et al.
2002). In addition, medication was received in the evening
in both studies in contrast with the current investigation
where treatment was administered in the morning. This
different time of drug administration could explain these
conflicting results. The reduction of REM sleep produced
by the antagonistic effects of olanzapine at muscarinic
cholinergic receptors is usually observed when data are
obtained soon after drug administration. Nevertheless, this
effect could disappear over time. Thus, the enhanced REM
sleep obtained in our study could represent a kind of
rebound response to the previous acute daytime REM
mechanism disruption.
Risperidone showed increases in stage 2 and decreases
in REM sleep with a tendency to increase REM latency. In
addition, wake time in minutes and the number of stage
shifts were significantly reduced. These results agreed with
the only previous paper dealing with risperidone and
healthy volunteers (but given 90 min before retiring to
sleep; Sharpley et al. 2003). The pharmacological mecha-
nism by which risperidone might lower REM sleep is not
clear, but a similar effect has been noted in the rat (Dugovic
et al. 1989). Risperidone does have some antagonist activity
Fig. 2 Time course of EEG slow-wave activity (SWA, 0.5–4.0 Hz
range; C4A1-derivation) and spindle frequency activity (SFA, 11.0–
15.0 Hz range; C4A1-derivation), together with delta EOG activity
(DEA, 0.5–4.0 Hz range; EOG-derivation) plotted after one single oral
morning administration of olanzapine 5 mg, risperidone 1 mg and
haloperidol 3 mg (continuous curves) against placebo (dashed curves).
For each subject, individual NREMS episodes were subdivided into
20 equal time binds. Data were averaged across subjects (n=17) and
plotted against the mean timing of NREMS. Dashed vertical lines
delimit NREMS episodes. Triangles indicate NREMS episodes with a
significant AUC effect (t test for repeated measures); orientation of the
triangles indicates the direction of deviation from placebo
Table 3 Subjective sleep and awakening quality measures after one single oral morning administration of olanzapine 5 mg, risperidone1mg and
haloperidol 3 mg (mean±SEM; n=17)
Control Placebo Olanzapine Risperidone Haloperidol Manova Paired t test
SSA-T 31.2±5.54 34.3±7.2 33.1±5.8 37.3±9.1 33.3±5.3 0.347
SSA-1 11.7±4.50 14.5±4.3 11.9±2.02 15.1±4.07 13.6±3.1 0.029 O vs R**; O vs H*; O vs P+
SSA-2 14.1±3.55 14.4±3.2 15.4±3.9 16.2±4.5 14.2±3.4 0.169
SSA-3 5.4±0.77 5.3±0.7 5.9±0.9 6.0±2.02 5.4±0.65 0.229
SSL (min) 25.7±35.92 33.1±45.9 11.8±14.03 25.7±37.02 13.7±13.9 0.146
SSE (min) 89.6±9.27 85.9±16.3 91.8±9.9 86.3±12.2 91.05±9.1 0.147
SSA Self-assessment scale for sleep and awakening quality, T total score, 1=subjective sleep quality, 2=subjective awakening quality, 3=somatic
complains, SSL subjective sleep latency, SSE subjective sleep efficiency, P placebo, O olanzapine, R risperidone, H haloperidol
+p<0.10
*p<0.05
**p<0.01
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at noradrenergic α2-adrenoceptors (Janssen et al. 1988) and
α2-adrenoceptor antagonists such as idazoxan decrease
REM sleep, perhaps through facilitating epinephrine and
5-HT neurotransmission (Nicholson and Pascoe 1991).
Risperidone presents a potent 5-HT2A and a relatively
potent 5-HT2C receptor antagonist activity at low doses.
Therefore, the increase in stage 2 and not in SWS obtained
in our study would agree with the implication of the 5-HT2
receptors subtypes in SWS, already mentioned above in this
paper.
The treatment that produced fewest changes in PSG
variables was haloperidol. We observed only a tendency
towards an increase in sleep efficiency and stage 2 duration
and towards a decrease in wake time. Kinetics and
dynamic reasons could be at the base of these scanty
results. Haloperidol (18 h) has a considerably shorter half-
life than olanzapine (33 h) and risperidone (parent
compound, 3 h but an active metabolite −9,hydroxyrisper-
idone-, 27 h). Thus there were clear differences in the
availability of the active compounds when the measures
were obtained. Moreover, like all typical antipsychotics,
haloperidol is devoid of any direct activity on serotonin-
ergic receptors. In addition, it is the highest selective
dopamine D2 blocker, and it has no antimuscarinic or
antihistaminic binding potential. In contrast with the well-
known role of other neurotransmitter systems in sleep
physiology, the consequences of specific dopamine manip-
ulations are far from being clearly understood (Pace-Schott
and Hobson 2002). However, the results obtained fall in the
line with the global improvement in sleep continuity
generally described after antipsychotic administration in
schizophrenic patients (Stephan et al. 1991; Maixner et al.
1998). Specifically, patients under haloperidol treatment
usually show increases in TST and sleep efficiency but no
change, or even a decrease, in the amount of SWS (Itil et al.
1970).
Regarding spectral evaluations, in all-night analysis,
olanzapine showed a markedly depressed power density in
the high-frequency range during all sleep stages and an
additional reduction in the low frequency band in SWS.
However, dynamics of SWA did not reach statistically
significant differences, whereas a significant reduction on
the SFA in the second and fourth NREMS episodes was
obtained. These results are quite different from those
obtained after a higher (10 mg) evening (18.0 h) dose of
olanzapine, which consisted of only significant increases in
theta power mainly in female healthy subjects (Lindberg et
al. 2002). Furthermore, they are also different from results
after more selective 5-HT2 receptor antagonists, which in
addition to a decrease in sigma activity also induced an
increase in delta activity, both in rats (Bobérly et al. 1988)
and in humans (Dijk et al. 1989; Viola et al. 2002). It is
interesting to note that changes in wake EEG after an acute
drug intake in healthy volunteers mainly consisted of
increases in delta and theta, but decreases in alpha and
beta activities (Saletu et al. 1987b). In the current
investigation, risperidone mainly presented increases in
the 3.6–10.8 Hz frequency band in all night NREM
spectrum without significant changes in SWA and SFA
dynamics, and haloperidol induced significant power
increases in the high frequency range in NREM all
spectrum together with a significant increase of SFA
circumscribed to the first NREM episode. We are unable
to compare our results as to our knowledge no other studies
have yet been carried out evaluating risperidone or
haloperidol effects on spectral sleep EEG analysis. Inter-
estingly, the obtained changes resembled those observed in
wake EEG in healthy volunteers after single oral doses of
these compounds, risperidone inducing increases on delta,
theta and alpha-1 activities and haloperidol increases on
alpha and beta activities (Saletu et al. 1987b; Lee et al.
1999). Analysis of eye-movement density during stage
REM, represented by the dynamics of slow activity in EOG
channels during REM sleep, revealed no changes after any
of the treatments. Data on neuroleptic effects on phasic
REM variables are scarce and inconclusive (Salin-Pascual
et al. 1999).
When subjective sleep perception was taken into
account, subjective sleep quality was the only variable
which presented statistically significant results, showing a
clear improvement after olanzapine. Subjective sleep
quality seems to be related to the perceptions of ease
of initiation and maintenance of sleep but unrelated to
the ease of awakening (Åkerstedt et al. 1994a,b). From a
physiological point of view, subjective sleep quality has
been related with the amount of SWS (Åkerstedt et al.
1997). The results reported by the participants are therefore
in good agreement with these previous described PSG
findings.
In summary, antipsychotics showed clear sleep changes
in healthy subjects after single morning oral doses,
supporting non-biased pharmacological effects when ad-
ministered even 15 h before going to bed. This finding
demonstrates that sleep mechanisms are very sensitive to
the sedation reportedly observed after intake of most
antipsychotics. Effects varied as neurochemical profiles of
the compounds were different. The impact on night sleep
should be expected not only when these drugs are
prescribed at night-time but even if they are taken in a
morning administration schedule.
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